Compare MESO & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | ASTH |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | Australia | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | N/A | 2015 |
| Metric | MESO | ASTH |
|---|---|---|
| Price | $13.93 | $38.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $34.86 |
| AVG Volume (30 Days) | 136.6K | ★ 420.3K |
| Earning Date | 02-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | ★ $519,907,752.00 |
| Revenue This Year | $629.74 | $27.38 |
| Revenue Next Year | $30.65 | $10.78 |
| P/E Ratio | ★ N/A | $137.41 |
| Revenue Growth | N/A | ★ 45.90 |
| 52 Week Low | $9.88 | $18.08 |
| 52 Week High | $21.50 | $40.13 |
| Indicator | MESO | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 56.09 |
| Support Level | $13.71 | $36.95 |
| Resistance Level | $16.14 | $39.93 |
| Average True Range (ATR) | 0.47 | 1.45 |
| MACD | -0.07 | -0.18 |
| Stochastic Oscillator | 11.08 | 56.11 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.